MedDataX Logo

Neutrophil Gelatinase-associated Lipcalin(NGAL): A Novel Blood Marker for Determining the Risk of Developing Contrast-Induced Nephopathy

NCT ID: NCT00693329

Last Updated: 2009-12-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

260 participants

Study Classification

OBSERVATIONAL

Study Start Date

2008-03-31

Study Completion Date

2009-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a multi-center clinical study designed to assess the performance of the Triage NGAL test as an aid in the early risk assessment for contrast-induced nephropathy (CIN). Approximately 260 adults at risk for CIN undergoing intra-arterial angiography involving administration of iodinated contrast agent(s) will be enrolled.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

EDTA anti-coagulated blood samples will be drawn at eight different time points from within 1 hour prior to first contrast administration through 48 hours. These blood samples will be processed to plasma at the clinical site, frozen and shipped to Biosite for storage and testing of Triage NGAL and serum creatinine. The results of these assessments will be blinded to the medical team during the study and will not impact the medical management of the subject.

Any additional serum creatinine measurements obtained by the medical team as part of routine care as well as need for dialysis, hospitalization, major adverse cardiovascular events and mortality will be recorded through Day 30.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cardiovascular Surgery With Coronary Angiography

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Contrast Induced Nephrophathy (CIN) Kidney NGAL

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Males and females 18 years of age or older;
* Undergoing angiographic procedure involving the intra-arterial administration of iodinated contrast agent(s);
* Chronic kidney disease indiacated by an eGFR \< 75 ml/min/1.73 m2 based on screening labs performed ≤ 3 months prior to procedure.
* Able and willing to provide written informed consent for study participation and to comply with all study procedures.

Exclusion Criteria

* Renal transplant recipients
* Pre-existing evidence of acute renal failure at the time of enrollment.
* Already receiving dialysis (either acute or chronic) or in imminent need of dialysis at enrollment.
* Coronary artery bypass surgery or PCI within the previous 30 days.
* Participation in an interventional clinical study with an experimental therapy within the previous 30 days.
* Administration of intravasular contrast within the previous 30 days.
* Undergoing renal artery stenting.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Abbott RDx Cardiometabolic

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Biosite

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Peter McCullough, MD

Role: PRINCIPAL_INVESTIGATOR

William Beaumont Hospitals

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Cardiac and Vascular Research Center of Northern Michigan

Petoskey, Michigan, United States

Site Status

Providence Hospital

Providence, Michigan, United States

Site Status

William Beaumont Hospital

Royal Oak, Michigan, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

BSTE-0406

Identifier Type: -

Identifier Source: org_study_id